Celecoxib in NSCLC: The roles of elevated COX-2 and CA-IX in NSCLC growth promotion, along with the potential benefit of celecoxib in NSCLC treatment, were recently reviewed [56,57,58]. This evidence concerns the gene CA9 and non-small cell lung carcinoma.